Q1 Earnings Estimate for Zymeworks Issued By Lifesci Capital

Zymeworks Inc. (NYSE:ZYME) – Equities research analysts at Lifesci Capital increased their Q1 2026 earnings per share estimates for shares of Zymeworks in a note issued to investors on Monday, October 6th. Lifesci Capital analyst C. Zhu now expects that the company will earn $0.48 per share for the quarter, up from their prior estimate of $0.47. The consensus estimate for Zymeworks’ current full-year earnings is ($1.39) per share.

Zymeworks (NYSE:ZYME) last issued its earnings results on Thursday, August 7th. The company reported $0.03 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.52) by $0.55. The business had revenue of $48.73 million during the quarter, compared to the consensus estimate of $17.18 million. Zymeworks had a negative return on equity of 23.00% and a negative net margin of 182.75%.The company’s revenue for the quarter was up 153.2% on a year-over-year basis. During the same period in the prior year, the business posted ($0.49) EPS.

Several other equities analysts also recently weighed in on ZYME. HC Wainwright reaffirmed a “neutral” rating and issued a $13.00 price objective on shares of Zymeworks in a research note on Thursday, July 3rd. Citigroup raised their price objective on Zymeworks from $19.00 to $22.00 and gave the company a “buy” rating in a research note on Monday, August 11th. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $21.43.

Zymeworks Price Performance

NYSE ZYME opened at $16.68 on Wednesday. Zymeworks has a 1-year low of $9.03 and a 1-year high of $17.70. The company has a market capitalization of $1.25 billion, a P/E ratio of -11.12 and a beta of 1.51. The business has a 50 day moving average price of $14.96 and a 200 day moving average price of $13.20.

Hedge Funds Weigh In On Zymeworks

Several hedge funds have recently bought and sold shares of the stock. Assenagon Asset Management S.A. increased its position in Zymeworks by 169.2% during the third quarter. Assenagon Asset Management S.A. now owns 1,326,774 shares of the company’s stock worth $22,661,000 after buying an additional 833,994 shares in the last quarter. Squarepoint Ops LLC grew its position in shares of Zymeworks by 144.6% in the second quarter. Squarepoint Ops LLC now owns 155,599 shares of the company’s stock valued at $1,953,000 after purchasing an additional 91,997 shares during the period. Tower Research Capital LLC TRC grew its position in shares of Zymeworks by 29.6% in the second quarter. Tower Research Capital LLC TRC now owns 4,947 shares of the company’s stock valued at $62,000 after purchasing an additional 1,131 shares during the period. Vestal Point Capital LP lifted its holdings in shares of Zymeworks by 130.0% during the 2nd quarter. Vestal Point Capital LP now owns 1,150,000 shares of the company’s stock worth $14,432,000 after acquiring an additional 650,000 shares during the period. Finally, Rubric Capital Management LP lifted its holdings in shares of Zymeworks by 8.6% during the 2nd quarter. Rubric Capital Management LP now owns 4,710,551 shares of the company’s stock worth $59,117,000 after acquiring an additional 372,107 shares during the period. Hedge funds and other institutional investors own 92.89% of the company’s stock.

Zymeworks Company Profile

Zymeworks Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company’s lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors.